Last deal

$17M

Amount

Series B

Stage

02.02.2010

Date

2

all rounds

$23.47M

Total amount

date founded

Financing round

General

About Company
Altair Therapeutics develops and sells antisense drugs for respiratory diseases like asthma.

Industry

Sector :

Subsector :

founded date

01.01.2007

Operating Status

Closed (01.05.2013)

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

Founded in 2007, Altair Therapeutics focused on developing therapeutics to treat human respiratory diseases, with a particular emphasis on asthma. One of its key products was AIR645, an inhaled drug used for the treatment of asthma and rhinitis. However, as of May 1, 2013, the company has closed its operations.
Contacts
Similar Companies
1000
Enterprise Therapeutics

Enterprise Therapeutics

Enterprise Therapeutics develops novel therapies for respiratory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Falmer, Brighton BN1, UK

total rounds

8

total raised

$97.09M
Enalare Therapeutics

Enalare Therapeutics

Enalare Therapeutics Inc. develops and commercializes novel therapies for acute respiratory and critical care conditions.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Therapeutics

Location

Naples, FL, USA

total rounds

6

total raised

$73.85M

Lazarus Therapeutics

Lazarus Therapeutics is developing therapeutics for Parkinson's disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

West Chester, PA, USA
Modus Therapeutics

Modus Therapeutics

Modus Therapeutics develops pharmaceutical therapies to restore impaired blood flow in rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Stockholm, Sweden

total rounds

4

total raised

$21.14M

Financials

Funding Rounds
2
2

Number of Funding Rounds

$23.47M

Money Raised

Their latest funding was raised on 02.02.2010. Their latest investor Thomas, McNerney & Partners. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
02.02.2010
4
$17M
17.11.2009
$6.47M
Co-Investors
Investors
4
0

Number of lead investors

4

Number of investors

Investor 
Lead 
Round 
Partners 
Thomas, McNerney & Partners

Thomas, McNerney & Partners

Thomas, McNerney & Partners is a healthcare venture capital firm.

Sector

Medical Equipment and Services

Subsector

Medical Equipment

Keywords

Medical Device, Health Care, Venture Capital

Location

Stamford, CT, USA

count Of Investments

43

count Of Exists

15
Pratik Shah

Pratik Shah

Pratik Shah is the Executive Chairman of Design Therapeutics.

current job

Design Therapeutics
Design Therapeutics
Domain Associates

Domain Associates

Domain Associates is a venture capital firm that invests exclusively in life sciences.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

San Diego, CA, USA

count Of Investments

241

count Of Exists

65
AgeChem Venture Fund

AgeChem Venture Fund

AgeChem Fund L.P. is a venture capital firm that invests in companies developing therapeutics for age-related diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Dorval, QC, Canada

count Of Investments

14

count Of Exists

3

People

Founders
1
Susan Gregory
Susan Gregory

Susan Gregory

organization founded

1

Susan Gregory

Employee Profiles
3
Joel Martin, Ph.D.

Joel Martin, Ph.D.

President & Chief Executive Officer

Activity

Recent News
0